Zhong Jin Zai Xian·2026-03-31 05:15Core Viewpoint - Fosun International's Chairman Guo Guangchang stated that the RMB 23.4 billion impairment provision is a "prudent accounting treatment" and not indicative of operational issues, marking a new development phase for the company [1][2] Financial Performance - For the reporting period, Fosun International's total revenue reached RMB 173.43 billion, with adjusted operating profit at RMB 4 billion [2] - The four core subsidiaries generated revenue of RMB 128.2 billion, accounting for 74% of total revenue [2] - Fosun Pharma reported a net profit attributable to the parent of RMB 3.371 billion, a year-on-year increase of 21.69% [2] - Fosun Portugal Insurance achieved a net profit of EUR 201 million, up 15.8% year-on-year [2] Impairment and Strategic Focus - The company recorded a one-time non-cash impairment provision and value reassessment, resulting in an annual loss of RMB 23.4 billion, with 55% attributed to real estate impairments and 45% to non-core asset impairments [2] - Guo emphasized the company's commitment to exiting underperforming assets and focusing resources on high-growth core sectors for sustainable development [1][2] Future Outlook - The adjusted net asset value (NAV) is RMB 133.5 billion, with a per-share NAV of HKD 18.1 [2] - The board has announced a share buyback plan, and major shareholders and management will increase their holdings [2] - The company plans to explore more shareholder return initiatives, including optimizing the dividend mechanism [2]